ARS Pharmaceuticals
Yahoo Finance • 5 days ago
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-ris... Full story
Yahoo Finance • 15 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 15 days ago
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to marke... Full story
Yahoo Finance • last month
ARS Pharma drops 9% as Lupin files application for generic neffy
[Move down arrow on blackboard background] * ARS Pharmaceuticals (NASDAQ:SPRY [https://seekingalpha.com/symbol/SPRY]) is down ~9% in Friday trading after disclosing that Indian drugmaker Lupin has filed an ANDA with the U.S. FDA for a g... Full story
Yahoo Finance • 2 months ago
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists
ARS Pharmaceuticals Inc (NASDAQ:SPRY [https://www.chartmill.com/stock/quote/SPRY/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $15... Full story
Yahoo Finance • 2 months ago
ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M
* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20199129-ars-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-accelerating] (NASDAQ:SPRY [https://seekingalpha.com/symbol/SPRY]): Q2 GAAP EPS of... Full story
Yahoo Finance • 3 months ago
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to marketEURneffy in the U.K., expects avai... Full story
Yahoo Finance • 3 months ago
Silverback Therapeutics stock hits 52-week high at $18.59
Silverback Therapeutics Inc . (NASDAQ:SPRY) stock reached a significant milestone as it hit a 52-week high of $18.59, with the company now commanding a market capitalization of $1.81 billion. According to InvestingPro data, the stock’s tec... Full story
Yahoo Finance • 3 months ago
Ars pharma CCO Karas sells $240k in SPRY stock
Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a company whose stock has delivered a remarkable 104% return over the past year and currently commands a market capitalization of $1.55 billion, sold 15,000 s... Full story
Yahoo Finance • 4 months ago
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that cou... Full story
Yahoo Finance • 5 months ago
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
ARS Pharmaceuticals, Inc. $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promo... Full story
Yahoo Finance • 6 months ago
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money
We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) stands against other unstoppable stocks that could double you... Full story
Yahoo Finance • 7 months ago
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering... Full story
Yahoo Finance • 7 months ago
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to b... Full story
Yahoo Finance • 7 months ago
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary plat... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024 Resubmission of New Drug Application (NDA) for neffy® anticipated in H1 202... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy’s potential to be a safe and effective option across patient sub-populatio... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws
NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and d... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc.(SPRY)
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws. On Sep... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws. On Sep... Full story
